HeartFlow (HTFL) Stock Gets Fair Value Boost After Q2 Beat And Guidance Raise
Simply Wall St reports analyst fair value for HeartFlow (HTFL) rose from $37.00 to about $42.13 after Q2 results and guidance raised. Multiple firms lifted price targets into the $40 to $45 range, citing Q2 metric beats, higher gross margin expectations, and updates tied to 2026 guidance and product or clinical data. Assumptions include higher revenue growth and net margin.
How this was made
The 30-second read
Why it matters
It updates a fair value estimate and the underlying valuation assumptions (revenue growth, net profit margin, forward P/E), and notes that multiple firms lifted price targets into the $40 to $45 range while some maintain Neutral/Equal Weight caution.
Market read
For traders, the actionable takeaway is the market narrative shift toward higher 2026 expectations and improved margin assumptions, with valuation anchored in outer-year sales.
What to watch
The article highlights risks (slower Plaque uptake, competition in healthcare AI tools, potential additional capital needs) but does not quantify them, leaving uncertainty around how much of the valuation uplift is execution-dependent.
Background
The piece is a Simply Wall St valuation narrative that aggregates Street commentary following HeartFlow’s Q2 results and a raised 2026 guidance outlook.
Ticker impact
Simply Wall St says analyst fair value for HeartFlow rose from $37.00 to about $42.13 after Q2 beat and 2026 guidance raise.
Near-term sentiment likely supportive as PTs cluster in the low to mid $40s, but the piece also flags execution and reimbursement risks that could cap upside.
The text provides specific valuation-model deltas (fair value, revenue growth, net margin, forward P/E) and cites multiple PT lifts, but it is still a secondary synthesis rather than a primary company filing or new clinical/regulatory disclosure.
Market effects
Could modestly improve sentiment toward coronary CT angiography and plaque-analysis reimbursement narratives within cardiology diagnostics/healthcare AI.
No clear regional market linkage beyond US-listed analyst coverage.
Limited, as the article is US-focused analyst valuation discussion with no international regulatory or commercial expansion details.
Counterpoint
PT increases may reflect model optimism (higher margins, outer-year sales anchoring) rather than a durable change in adoption pace, so the stock could re-rate down if Plaque uptake or reimbursement traction disappoints.
Key entities
- companyHeartFlow
HTFL, discussed as having a Q2 beat and raised 2026 guidance that drove analyst fair value and price target increases.
- analyst_firmJPMorgan
Cited as lifting HeartFlow price targets into the $40 to $45 range after Q2 results.
- analyst_firmMorgan Stanley
Cited as maintaining Equal Weight despite target lifts, signaling caution on risk-reward.
